Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma

• Published in: Journal for immunotherapy of cancer Vol. 12; no. 5; p. e008817
• Main Authors: Mørk, Sofie Kirial, Skadborg, Signe Koggersbøl, Albieri, Benedetta, Draghi, Arianna, Bol, Kalijn, Kadivar, Mohammad, Westergaard, Marie Christine Wulff, Stoltenborg Granhøj, Joachim, Borch, Annie, Petersen, Nadia Viborg, Thuesen, Nikolas, Rasmussen, Ida Svahn, Andreasen, Lars Vibe, Dohn, Rebecca Bach, Yde, Christina Westmose, Noergaard, Nis, Lorentzen, Torben, Soerensen, Anders Bundgaard, Kleine-Kohlbrecher, Daniela, Jespersen, Anders, Christensen, Dennis, Kringelum, Jens, Donia, Marco, Hadrup, Sine Reker, Marie Svane, Inge
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 23.05.2024; BMJ Publishing Group LTD; BMJ Publishing Group
• Subjects: Adult; Aged; Antigens, Neoplasm - immunology; Biopsy; Cancer therapies; Cancer vaccines; Cancer Vaccines - administration & dosage; Cancer Vaccines - immunology; Cancer Vaccines - therapeutic use; Clinical trials; Clinical/translational cancer immunotherapy; Female; Humans; immunotherapy; Lymphocytes; Male; Manufacturing; Medical imaging; Melanoma; Melanoma - drug therapy; Melanoma - immunology; Metastasis; Middle Aged; Neoplasm Metastasis; Oncology; Patients; Peptides; Precision Medicine - methods; Tumors; vaccine; Vaccines, Subunit - administration & dosage; Vaccines, Subunit - immunology; Vaccines, Subunit - therapeutic use; vaccine; immunotherapy
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1136/jitc-2024-008817

BackgroundNeoantigens can serve as targets for T cell-mediated antitumor immunity via personalized neopeptide vaccines. Interim data from our clinical study NCT03715985 showed that the personalized peptide-based neoantigen vaccine EVX-01, formulated in the liposomal adjuvant, CAF09b, was safe and able to elicit EVX-01-specific T cell responses in patients with metastatic melanoma. Here, we present results from the dose-escalation part of the study, evaluating the feasibility, safety, efficacy, and immunogenicity of EVX-01 in addition to anti-PD-1 therapy.MethodsPatients with metastatic melanoma on anti-PD-1 therapy were treated in three cohorts with increasing vaccine dosages (twofold and fourfold). Tumor-derived neoantigens were selected by the AI platform PIONEER and used in personalized therapeutic cancer peptide vaccines EVX-01. Vaccines were administered at 2-week intervals for a total of three intraperitoneal and three intramuscular injections. The study’s primary endpoint was safety and tolerability. Additional endpoints were immunological responses, survival, and objective response rates.ResultsCompared with the base dose level previously reported, no new vaccine-related serious adverse events were observed during dose escalation of EVX-01 in combination with an anti-PD-1 agent given according to local guidelines. Two patients at the third dose level (fourfold dose) developed grade 3 toxicity, most likely related to pembrolizumab. Overall, 8 out of the 12 patients had objective clinical responses (6 partial response (PR) and 2 CR), with all 4 patients at the highest dose level having a CR (1 CR, 3 PR). EVX-01 induced peptide-specific CD4+ and/or CD8+T cell responses in all treated patients, with CD4+T cells as the dominating responses. The magnitude of immune responses measured by IFN-γ ELISpot assay correlated with individual peptide doses. A significant correlation between the PIONEER quality score and induced T cell immunogenicity was detected, while better CRs correlated with both the number of immunogenic EVX-01 peptides and the PIONEER quality score.ConclusionImmunization with EVX-01-CAF09b in addition to anti-PD-1 therapy was shown to be safe and well tolerated and elicit vaccine neoantigen-specific CD4+and CD8+ T cell responses at all dose levels. In addition, objective tumor responses were observed in 67% of patients. The results encourage further assessment of the antitumor efficacy of EVX-01 in combination with anti-PD-1 therapy.